Bio-Gene Technology Limited (ASX:BGT)

Australia flag Australia · Delayed Price · Currency is AUD
0.0210
0.00 (0.00%)
Aug 14, 2025, 4:10 PM AEST
Market Cap6.41M
Revenue (ttm)-435.00
Net Income (ttm)-2.36M
Shares Out305.06M
EPS (ttm)-0.01
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume260,954
Average Volume103,439
Open0.0210
Previous Close0.0210
Day's Range0.0210 - 0.0210
52-Week Range0.0160 - 0.0710
Beta0.35
RSI57.00
Earnings DateAug 22, 2025

About Bio-Gene Technology

Bio-Gene Technology Limited, an agtech development company, engages in the development and commercialization of naturally derived insecticide products in Australia and internationally. Its products include Flavocide, a synthetically produced nature-identical compound; Qcide, a natural plant-derived oil with high levels of tasmanone. The company has a research collaboration agreement with James Cook University to support research and field operations relating to processing and distillation of oil from biomass; AgriFor Scientific, a chemistry pro... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1995
Country Australia
Stock Exchange Australian Securities Exchange
Ticker Symbol BGT
Full Company Profile

Financial Performance

In 2024, Bio-Gene Technology's revenue was 18,320, a decrease of -87.72% compared to the previous year's 149,232. Losses were -2.41 million, -22.18% less than in 2023.

Financial Statements

News

There is no news available yet.